Aldosterone effects on glomerular structure and function

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 730-738

  Bernardi, Stella ^a   Toffoli, Barbara ^a,b   Zennaro, Cristina ^a   Bossi, Fleur ^a   Losurdo, Pasquale ^a   Michelli, Andrea ^a   Carretta, Renzo ^a   Mulatero, Paolo ^c   Fallo, Francesco ^d   Veglio, Franco ^c   Fabris, Bruno ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

ACE2; Aldosterone; ANP; Fibrosis; Glomerular permeability; Glomerulus; Oxidative stress

Indexed keywords

ALBUMIN; ALDOSTERONE; ANGIOTENSIN CONVERTING ENZYME 2; ATRIAL NATRIURETIC FACTOR; CONNECTIVE TISSUE GROWTH FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; EPLERENONE; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; MANGANESE SUPEROXIDE DISMUTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SODIUM CHLORIDE; SALT INTAKE;

ALBUMIN EXCRETION RATE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXCRETION; GENE EXPRESSION; GLOMERULAR FILTRATION BARRIER; GLOMERULAR STRUCTURE; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY SIZE; KIDNEY TUBULE; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; UNINEPHRECTOMY; WISTAR RAT; ANIMAL; DRUG EFFECTS; FIBROSIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE;

ALDOSTERONE; ANIMALS; FIBROSIS; GLOMERULAR FILTRATION RATE; KIDNEY GLOMERULUS; MALE; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY;

EID: 84952910490     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320315595568     Document Type: Article

References (52)

1. Funder JW,. Minireview: aldosterone and mineralocorticoid receptors: past, present, and future. Endocrinology 2010; 151: 5098-5102.
2. Odermatt A, Atanasov AG,. Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 2009; 74: 163-171.
3. Remuzzi G, Cattaneo D, Perico N,. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 2008; 19: 1459-1462.
4. Robert V, Heymes C, Silvestre JS, et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986.
5. Harada E, Yoshimura M, Yasue H, et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultural neonatal rat cardiocytes. Circulation 2001; 104: 137-139.
6. Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912.
7. Marney AM, Brown NJ,. Aldosterone and end-organ damage. Clin Sci 2007; 113: 267-278.
8. Blasi ER, Rocha R, Rudolph AE, et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800.
9. Rossi GP, Bernini G, Desideri G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48: 232-238.
10. Sechi LA, Novello M, Lapenna R, et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645.
11. Fujisawa G, Okada K, Muto S, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004; 66: 1493-1502.
12. Han KH, Kang YS, Han SY, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111-120.
13. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.
14. Rocha R, Rudolph AE, Frieedich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.
15. Acelajado MC, Pimenta E, Calhoun DA,. Salt and aldosterone. Hypertension 2010; 56: 804-805.
16. Kawarazaki W, Nagase M, Yoshida S, et al. Angiotensin II-and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 2012; 23: 997-1007.
17. Carraro M, Mancini W, Artero M, et al. Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. Diabetologia 2000; 43: 235-241.
18. Bernardi S, Toffoli B, Zennaro C, et al. High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. Nephrol Dial Transplant 2012; 27: 1793-1800.
19. Bernardi S, Zennaro C, Palmisano S, et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst 2012; 13: 202-209.
20. Bernardi S, Tikellis C, Candido R, et al. ACE2 deficiency shifts energy metabolism towards glucose utilization. Metabolism 2015; 64: 406-415.
21. Rossi GP, Barisa M, Belfiore A, et al. The aldosterone-renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010; 28: 1892-1899.
22. Shibata S, Nagase M, Yoshida S, et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007; 49: 355-364.
23. Welsh GI, Saleem MA,. The podocyte cytoskeleton: key to a functioning glomerulus in health and disease. Nat Rev Nephrol 2011; 8: 14-21.
24. Shih NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 1999; 286: 312-315.
25. Wang S, Wu H, Liu Y, et al. Expression of USP2-69 in mesangial cells in vivo and in vitro. Pathol Int 2010; 60: 184-192.
26. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
27. Agrawal V, Prasad N, Jain M, et al. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria. Clin Exp Nephrol 2013; 17: 811-818.
28. Satchell SC, Tooke JE,. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51: 714-725.
29. Van den Berg JG, van den, Bergh Weerman MA, Assmann KJ, et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66: 1901-1906.
30. Farquhar MG,. The glomerular basement membrane: not gone, just forgotten. J Clin Invest 2006; 116: 2090-2093.
31. Shibata S, Mu S, Kawarazaki H, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011; 121: 3233-3243.
32. Bunda S, Wang Y, Mitts TF, et al. Aldosterone stimulates elastogenesis in cardiac fibroblasts via mineralocorticoid receptor-independent action involving the consecutive activation of Galpha13, c-Src, the insulin-like growth factor-I receptor, and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2009; 284: 16633-16647.
33. Del Vecchio L, Procaccio M, Vigano S, et al. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol 2007; 3: 42-49.
34. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010; 107: 888-897.
35. Tikellis C, Bernardi S, Burns WC,. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2011; 20: 62-68.
36. Varagic J, Ahmad S, Nagata S, et al. ACE2: angiotensin ii/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014; 16: 420-425.
37. Mizuiri S, Ohashi Y,. ACE and ACE2 in kidney disease. World J Nephrol 2015; 4: 74-82.
38. Wang J, Yu L, Solenberg PJ, et al. Aldosterone stimulates angiotensin-converting enzyme expression and activity in rat neonatal cardiac myocytes. J Card Fail 2002; 8: 167-174.
39. Yamamuro M, Yoshimura M, Nakayama M, et al. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J 2008; 72: 1346-1350.
40. Bernardi S, Burns WC, Toffoli B, et al. Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7). Clin Sci (2012; 123: 29-37.
41. Hernandez Prada JA, Ferreira AJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51: 1312-1317.
42. Liu CX, Hu Q, Wang Y, et al. Angiotensin-converting enzyme (ACE) 2 overexpression ameliorates glomerular injury in a rat model of diabetic nephropathy: a comparison with ACE inhibition. Mol Med 2011; 17: 59-69.
43. Soler MJ, Wysocki J, Ye M, et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72: 614-623.
44. Pinheiro SV, Ferreira AJ, Kitten GT, et al. Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 2009; 75: 1184-1193.
45. Kasahara M, Mukoyama M, Sugawara A, et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000; 11: 1691-1701.
46. Ogawa Y, Mukoyama M, Yokoi H, et al. Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol 2012; 23: 1198-1209.
47. Sharma R, Khanna A, Sharma M, et al. Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 2000; 58: 131-136.
48. Roestenberg P, van Nieuwenhoven FA, Joles JA, et al. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Renal Physiol 2006; 290: F1344-1354.
49. Ruster C, Wolf G,. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011; 22: 1189-1199.
50. Wahab N, Cox D, Witherden A, et al. Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1). Biochem J 2007; 406: 131-138.
51. Fuchshofer R, Ullmann S, Zeilbeck LF, et al. Connective tissue growth factor modulates podocyte actin cytoskeleton and extracellular matrix synthesis and is induced in podocytes upon injury. Histochem Cell Biol 2011; 136: 301-319.
52. Guha M, Xu ZG, Tung D, et al. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 2007; 21: 3355-3368.